Phase 3 Trial to Evaluate the Efficacy and Safety of COL-1620 Vaginal Progesterone Gel

This study has been completed.
Information provided by (Responsible Party):
Merck KGaA Identifier:
First received: May 23, 2013
Last updated: November 23, 2014
Last verified: November 2014
The primary objective of this trial is to demonstrate the non-inferiority of the clinical pregnancy rate per embryo transfer to the historical standard value in in-vitro fertilization (IVF)/embryo transfer (ET) cycles in Japan (Japan Society of Obstetrics and Gynecology [JSOG] 2009 registry data: 24.3 percent [%]). The secondary objectives of this trial are to assess the biochemical pregnancy rate per ET, pharmacokinetics, and safety of COL-1620.

Condition Intervention Phase
Luteal Hormone Supplementation in In-vitro Fertilization
Embryo Transfer
Drug: COL-1620
Drug: Gonadotropin-releasing hormone (GnRH) analogue
Drug: Follicle-stimulating hormone (FSH)
Drug: Human Chorionic Gonadotropin (hCG)
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Open-label, Single-arm, Multicenter Phase III Trial to Evaluate the Efficacy and Safety of COL-1620 8% Vaginal Progesterone Gel for Luteal Phase Support in In-vitro Fertilization and Embryo Transfer (IVF/ET) Cycles in Japanese Women

Resource links provided by NLM:

Further study details as provided by Merck KGaA:

Primary Outcome Measures:
  • Percentage of subjects with Clinical pregnancy per Embryo Transfer [ Time Frame: Week 5 post embryo transfer ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Percentage of subjects with Biochemical pregnancy per Embryo Transfer [ Time Frame: Week 5 post embryo transfer ] [ Designated as safety issue: No ]
  • Serum progesterone level [ Time Frame: Day of human chorionic gonadotropin (hCG) administration and Day 14+/-3 post embryo transfer ] [ Designated as safety issue: No ]

Enrollment: 123
Study Start Date: July 2013
Study Completion Date: October 2014
Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: COL-1620 Drug: COL-1620
COL-1620 vaginal progesterone gel (1.125 grams of progesterone gel containing 90 milligram that is 8% gel) will be administered by the vaginal route once daily, from the day of ovum pick-up (OPU) until Week 12, or until the confirmation of miscarriage or extra-uterine pregnancy.
Drug: Gonadotropin-releasing hormone (GnRH) analogue
Subjects will undergo conventional controlled ovarian stimulation (COS) therapy for IVF/ET according to the Investigator's discretion using GnRH analogue (agonist or antagonist) preparation.
Drug: Follicle-stimulating hormone (FSH)
Subjects will undergo conventional COS therapy for IVF/ET according to the Investigator's discretion using FSH containing preparation.
Drug: Human Chorionic Gonadotropin (hCG)
Subjects will undergo conventional COS therapy for IVF/ET according to the Investigator's discretion using hCG preparation.


Ages Eligible for Study:   20 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Japanese race
  • Woman with a history of infertility and in whom IVF/ET is indicated
  • The COS therapy is GnRH analogue (agonist or antagonist) in combination with a FSH-containing preparation
  • Healthy premenopausal woman aged between 20 and 45 years (inclusive) and wishing to conceive
  • Body mass index (BMI) of 17.0 to 25.0 kilogram per square meter (kg/m^2) (inclusive)
  • A negative pregnancy test (urinary beta-hCG) prior to starting COS
  • Normal cervical smear result (Papanicolaou [PAP] test: Negative for Intraepithelial Lesion or Malignancy [NILM] or [Atypical Squamous Cells of Undetermined Significance {ASC-US} and Human Papillomavirus {HPV} negative]) within 12 months prior to the date of informed consent. If not available, a cervical smear and HPV test will be performed as part of Screening
  • No clinically significant abnormal findings in the Screening hematology, biochemistry and urinalysis parameters
  • Full comprehension of the study and voluntary written informed consent obtained in writing prior to any trial-related activities

Exclusion Criteria:

  • History of recurrent pregnancy loss (defined as 3 or more previous spontaneous abortions)
  • History of 3 or more consecutive cancelled or failed (no clinical pregnancy) IVF/ET cycles
  • Abnormal hemorrhage of the reproductive tract of undetermined origin
  • Any contraindication to being pregnant and/or carrying a pregnancy to term (for example, malformations of sexual organs or fibroid tumors of the uterus incompatible with pregnancy)
  • Uterine myoma requiring treatment
  • Extra-uterine pregnancy within the last 3 months prior to the date of informed consent
  • History or presence of intracranial tumor (for example, hypothalamic or pituitary tumor)
  • Presence of or suspected gonadotropin- or estrogen-dependent malignancy (for example, ovarian, uterine or mammary carcinoma)
  • Ovarian enlargement or cyst of unknown etiology
  • Breast-feeding or lactation
  • History of severe Ovarian Hyperstimulation Syndrome (OHSS) (Classification of OHSS Severity, as per Japan Reproductive/Endocrine Working Group)
  • Known Human Immunodeficiency Virus (HIV)-positive status, or a history of or current active infection with Hepatitis B or C
  • Known allergy or hypersensitivity to progesterone preparations or gonadotropin preparations and/or their excipients, or any contraindication to receive medication for controlled ovarian stimulation (for example, gonadotropin, GnRH analogues, combined oral contraceptive pill, as appropriate)
  • History of or suspected alcohol or substance abuse within 5 years prior to the date of informed consent
  • Clinically significant systemic disease (for example, insulin-dependent diabetes, epilepsy, severe migraine, acute porphyria, hepatic, renal or cardiovascular disease, severe corticosteroid-dependent asthma)
  • Active thrombophlebitis, thromboembolic disorder or cerebral apoplexy, or a history of such conditions
  • Other significant disease that in the Investigator's or Sub-Investigator's opinion would exclude the subject from the trial
  • Participation in another clinical trial within 3 months prior to the date of informed consent or simultaneous participation in another clinical trial
  • Legal incapacity or limited legal capacity
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01863680

Research site
Fujimino, Japan
Research site
Kobe, Japan
Research site
Osaka, Japan
Research site
Sagamihara, Japan
Research site
Yokohama, Kanagawa, Japan
Sponsors and Collaborators
Merck KGaA
Study Director: Medical Responsible Merck KGaA
  More Information

No publications provided

Responsible Party: Merck KGaA Identifier: NCT01863680     History of Changes
Other Study ID Numbers: EMR200113_001
Study First Received: May 23, 2013
Last Updated: November 23, 2014
Health Authority: Japan: Pharmaceuticals and Medical Devices Agency

Keywords provided by Merck KGaA:
progesterone gel
Fertilization in Vitro
Embryo Transfer

Additional relevant MeSH terms:
Chorionic Gonadotropin
Follicle Stimulating Hormone
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses processed this record on November 27, 2015